Revelation Biosciences, Inc. REVB PHARMA
Company Overview
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Why Investors Should Care
Trades at a P/E of 0.0, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -89.98% |
| 6 Months: | -21.09% |
| 3 Months: | +0.00% |
| 1 Month: | -11.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.48 · Neutral
P/E of 0.04 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 91.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | REVB Revelation Biosciences, Inc. PHARMA | 1.01 | 0.04 | $4.02M | 0.00% | -94.64% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09M | 2.46M | 1.94M | 2.57M | 3.09M |
| Operating Income | - | - | - | -2.61M | -2.44M | -3.04M | -6.59M | -1.86M | -1.20M | -1.62M | -1.93M | -2.78M | -1.90M | -2.52M | -1.80M | - | -2.09M | -2.46M | -1.94M | -2.57M | -3.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.09M | -2.45M | -1.94M | -2.57M | -3.09M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.05M | -2.44M | -1.91M | -2.51M | -3.01M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.16K | -521 | -868 | -2.61M | -2.47M | -3.04M | -6.62M | -1.83M | -1.17M | 6.16M | -1.45M | -2.63M | -2.68M | -8.39M | -2.24M | - | -2.05M | -2.44M | -1.91M | -2.51M | -3.01M |
| Diluted EPS | - | - | - | - | -0.39 | -0.48 | -15.90 | -4.16 | -1.91 | 37.07 | -5.83 | -9.94 | -39.37 | -246.27 | -40.15 | - | -25.32 | -84.12 | -7.08 | -1.65 | -2.71 |
| R&D Expense | - | - | - | 1.56M | 1.16M | 1.53M | 3.68M | 975.58K | 381.57K | 525.27K | 909.28K | 1.65M | 717.58K | 1.39M | 830.98K | - | 858.83K | 1.32M | 922.86K | - | 1.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 10.86M | 8.66M | 7.98M | 9.07M |
| Operating Income | - | - | -11.95M | -10.86M | -8.66M | -7.98M | -9.07M |
| EBITDA | - | - | - | -10.84M | -8.63M | -7.95M | -9.04M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -10.83M | -120.25K | -15.04M | -8.91M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -3.64K | -1.63M | -11.99M | -10.83M | -120.25K | -15.04M | -8.91M |
| Diluted EPS | - | - | -42.50 | -91,775.84 | -101.28 | -1,052.16 | -23.95 |
| R&D Expense | - | - | 6.91M | 5.38M | 4.15M | 3.55M | 4.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 22.67K | 74.16M | - | 5.50M | 12.21M | 6.62M | 11.58M |
| Current Assets | - | - | - | 5.41M | 12.15M | 6.57M | 10.81M |
| Cash & Equivalents | - | 11.73K | - | 5.25M | 11.99M | 6.50M | 10.70M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | 26.31K | 6.34M | - | 4.45M | 5.56M | 1.91M | 2.72M |
| Current Liabilities | 26.31K | 3.43M | - | 4.45M | 5.56M | 1.91M | 2.00M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | 16.75K | 0 | - | 0 | 746.78K |
| Total Equity | -3.64K | 3.41M | - | 1.05M | 6.65M | 4.71M | 8.86M |
| Shares Outstanding | - | - | - | 118 | 1.38K | 43.52K | 1.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -216.66K | - | -11.22M | -7.29M | -18.32M | -8.27M |
| Investing Cash Flow | -74.04M | - | 0 | 0 | -19.17K | 0 |
| Financing Cash Flow | 74.26M | - | 15.20M | 14.03M | 12.85M | 12.47M |
| Capital Expenditure | - | -131.96K | - | - | -19.17K | - |
| Free Cash Flow | - | - | -11.22M | -7.29M | -18.34M | -8.27M |
| Net Change in Cash | - | - | 3.98M | 6.74M | -5.49M | 4.20M |
| Share Buybacks | - | 35.50M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 100.0% | -47.8% | - | -1,029.0% | -1.8% | -319.4% | -100.6% |
| ROCE % | - | - | - | -1,032.3% | -130.2% | -169.4% | -94.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sabby Management, LLC | 5.29% | 210.58K | $195.93K |
| 2 | Citadel Advisors Llc | 0.97% | 38.58K | $35.89K |
| 3 | Geode Capital Management, LLC | 0.43% | 17.19K | $15.99K |
| 4 | HRT Financial LP | 0.43% | 16.98K | $15.80K |
| 5 | Vanguard Fiduciary Trust Co | 0.33% | 13.13K | $12.21K |
| 6 | Tower Research Capital LLC (TRC) | 0.16% | 6.53K | $6.07K |
| 7 | Royal Bank of Canada | 0.02% | 747 | $695 |
| 8 | SBI Securities Co., Ltd. | 0.01% | 344 | $320 |
| 9 | Harbour Investments, Inc. | - | 41 | $38 |
| 10 | Barclays Plc | - | 168 | $156 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for REVB
Revelation plans to test Gemini in patients with acute kidney injury - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOM3F4dW1KdmZTN0F1LWI0NlZiejRHOENISGRnS2NPTkFRcTRxYnYwY3czekJhRXlJZW10OE9TazNKRFNtRXhFRFo3TUFubWVtQ0pkbEtaQW9oNng1WXdQUEVrVFBhWFBiMDFnVkNSbGpYUWt4T2ZZNnEyVTR2SEZnV0g4cG1KMUR2SmxSeF…
REVB Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5PZVR4eW9KZnpyMnl5RUlTTFVZZ3lCRXA2c3F1V0diVGJndS1sRVZkR3paWmNJV2JCV2pqaEh0QTFlekJOR0NGR1lqWmZzZEZBRXlMTHhNMDlaWkM0djFhQ1ZheTNuZDBfWlZCakEzNFU3UlI3Z1dPODBn?oc=5" target="_blank">REV…
REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNcXRKUWVCZlpwYzFyS1YyRUxSb0RDTmpMM2pHLTNLb2RhM1B4cG5KdmQxT2NWTmpzVXJSVFRHTUhURVNhUWJYemRlcmpJSXZVeW5yWk1CWkx2OU5GR1U1QU5BRGF1eHF2TENSNm1qZ0VZTWhsRUxvOWpFY1Y3UkhHOUpncEpMc1lQMlZEbT…
Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Stock News, REVB Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE1zVE9uRG5QVkFfbDdFNDRXc2RwdlI0SV9XQzdqeUw4TkZWZDhNblFJdWp0M29nOFVOTXhPZzZRbmZOdzlTWHNCVFdJNkVsd1FuRjNB?oc=5" target="_blank">Revelation Biosciences Inc (NYSE: REVB) Share Price, RE…
REVB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1jQXpkOXBidFZuLU82VWNwaHhoa3A5Q1FCVm5LcU9HWU9Fa0VXYnFjLTVxUDJxN3JUWnZlVHJzYVpNSzRBWFE?oc=5" target="_blank">REVB</a> <font color="#6f6f6f">Finviz</font>…
Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Stock News, REVB Share Price & Updates - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE14cGpDcWlzSm5GdzJFVkoyTFkxa1IxRUdqVlc0c1FFaGFtVDJFUU9la3ZTcFVFZlZBU2NvSVZ1QzlpOE5Ia2RNVWd4R0tjdw?oc=5" target="_blank">Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Sto…
REVB — Frequently Asked Questions
What is the current share price of Revelation Biosciences, Inc. (REVB)?
As of 2026-09-19 21:16 PDT, Revelation Biosciences, Inc. (REVB) trades at $1.01 on NasdaqCM. Its 52-week range is $0.95 to $11.72.
What is the market capitalisation of REVB?
Revelation Biosciences, Inc. (REVB) has a market capitalisation of $4.02M on NasdaqCM.
What is the P/E ratio of REVB?
REVB trades at a trailing price-to-earnings (P/E) ratio of 0.04. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.36.
Is REVB a good stock to buy?
This page provides a data-driven analysis of Revelation Biosciences, Inc. (REVB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.